• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Names Kevin Fuller Global Chief Marketing Officer

    9/16/24 2:00:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email

    Nature's Sunshine Products, Inc.

    LEHI, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Kevin Fuller as Global Chief Marketing Officer, effective September 23, 2024.

    Fuller, a seasoned marketing executive with over two decades of experience in high-performance organizations, brings in-depth global marketing experience to Nature's Sunshine. His deep understanding of the dietary supplement industry combined with his experience launching new products, building powerful brands, and driving customer growth strategies make Fuller an ideal fit for Nature's Sunshine.

    "We are very pleased to welcome Kevin to Nature's Sunshine," said Terrence Moorehead, Chief Executive Officer. "He brings a wealth of experience and a proven track record of developing successful marketing strategies. Kevin will be instrumental in helping take our brand to the next level, and we look forward to his many contributions."

    Fuller joins Nature's Sunshine from Helo Health, where he served as President and Chief Marketing Officer. Prior to his time with Helo Health, he was CEO and Chief Marketing Officer at MacuVu Macular Health where he developed the company's go-to-market strategy, brand identity, and product launch plans. Prior to that, he led NuSkin's marketing organization, as Senior Vice President, Global Product & Brand where he built a global marketing engine that improved consumer insights, modernized campaigns, and built an innovative product pipeline to drive sustainable growth. Earlier in his career, Fuller held key marketing roles at Pharmanex and USANA.

    "My passion for driving health and wellness transformation through innovative products aligns seamlessly with Nature's Sunshine's vision and mission. This iconic brand, with a rich legacy, is perfectly positioned for its next phase of growth. I am excited to partner such a strong leadership team to unlock Nature's Sunshine's full potential."

    Fuller holds an MBA from Brigham Young University, a B.S. in Biology from the University of Utah, and was a member of the Kellogg school's Executive Education Program for Digital Marketing. He is also an accomplished triathlete, competing in four Ironman World Championships, was selected as a member of the USA World Championship Triathlon Team in 2023 and is a current 3-time All American. He is also a member of the Advisory Board of Unleash Health.

    About Nature's Sunshine

    Nature's Sunshine Products (NASDAQ:NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature's Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.

    Investor Relations:

    Gateway Group, Inc.

    Cody Slach

    1-949-574-3860

    NATR@gateway-grp.com

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/56e21423-3878-4242-a7f4-c002d9a24634



    Primary Logo

    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    6/3/26 6:44:18 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/22/26 11:59:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/20/26 12:17:48 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form S-8 filed by Nature's Sunshine Products Inc.

    S-8 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/15/26 4:52:47 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/11/26 8:46:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/7/26 5:19:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care